Treatment algorithm for moderate to severe ulcerative colitis

Practical consensus recommendations

Michael Manz, Pierre Michetti, Frank Seibold, Gerhard Rogler, Christoph Beglinger

Department of Gastroenterology and Internal Medicine, St. Clarapital Basel, Switzerland
Department of Gastroenterology and Hepatology, University of Lausanne, Switzerland
Department of Gastroenterology and Hepatology, Tiefenau Spital Bern, Switzerland
Department of Gastroenterology and Hepatology, University of Zürich, Switzerland
Department of Gastroenterology and Hepatology, University of Basel, Switzerland

1 and the following experts (in alphabetical order):
C. Braegger, Zurich; F. Eigenmann, Baden; Ch. Felley, Lausanne; C. Gaia, Bellinzona; C. Meyenberger, St. Gallen; B. Sauter, Zurich; V. Stenz, Muensterlingen A. Straumann, Olten

Summary

The care for a patient with ulcerative colitis (UC) remains challenging despite the fact that morbidity and mortality rates have been considerably reduced during the last 30 years. The traditional management with intravenous corticosteroids was modified by the introduction of ciclosporin and infliximab. In this review, we focus on the treatment of patients with moderate to severe UC. Four typical clinical scenarios are defined and discussed in detail. The treatment recommendations are based on current literature, published guidelines and reviews, and were discussed at a consensus meeting of Swiss experts in the field. Comprehensive treatment algorithms were developed, aimed for daily clinical practice.

Key words: ulcerative colitis; treatment algorithm; moderate to severe ciclosporin; infliximab; fulminating; steroid-refractory; steroid-dependent; consensus-conference

Introduction

Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory disorder of the gastrointestinal tract, and, besides Crohn’s disease (CD), it is one of the two major forms of inflammatory bowel disease (IBD) [1]. The aetiology of UC remains unclear. Medical therapies to completely cure the disease are not available. Genetic, immunologic and environmental factors are likely to play a role in UC pathogenesis. Currently, the most widely accepted hypothesis implicates a combination of the following factors: immune deregulation (caused by genetic or environmental factors), abnormal gastrointestinal (GI) tract

luminal factors, (such as microorganisms constituting the GI tract flora, oxidative stress, and tumour necrosis factor (TNF)-alpha) and defects in the GI mucosal barrier that allow luminal factors to penetrate into the mucosa [2–7]. The clinical presentation of UC is characterised by abdominal pain, diarrhoea with or without haematochezia, and mucosal ulcerations [8]. The extent of disease varies from limited involvement of the rectum to involvement of the whole colon, and seldom of the terminal ileum (backwash ileitis). Clinically, mild disease is associated with fewer than 4 bowel movements per day, with or without bloody stools but without systemic manifestations and blood tests are usually normal. Moderate disease is associated with more than 4 bowel movements a day with minimal systemic manifestations. The simplest clinical measure to distinguish moderate from mildly active colitis is the presence of mucosal friability (bleeding on light contact with the rectal mucosa at sigmoidoscopy) [9]. Severe disease describes disease associated with more than 6 bowel movements a day, with blood in the stool and with systemic involvement [10, 11] (table 1). During relapses or flares, pharmacological or surgical intervention is needed to re-establish symptom free remission. Ideally, medical strategies are employed to maintain patients in long-term remission, while minimising steroid dependence and therapy-related toxicity. While most acute flares of UC are mild and manageable on an ambulatory basis, more severe flares requiring hospitalisation appear in about 15% of all cases [12]. Thirty to forty years ago, mortality in these patients reached up to 25%. With the introduction of intravenous corticosteroids, modern intensive care treatment, earlier recognition of treatment failure and advanced surgical techniques, mor-
tality has decreased to less than one percent in specialised centres [11, 13, 14].

In this review, we focus on the treatment of patients with moderate to severe UC. Four typical clinical scenarios are defined and discussed in detail. The recommendations are based on the current literature and published guidelines and reviews [15–20] (up to end of 2009). They were finally discussed at a consensus meeting (22nd June 2010) with the above mentioned IBD experts. Based on the discussion, a comprehensive treatment algorithm could be developed and was agreed upon by the board members. These treatment algorithms are aimed for daily clinical practice at colleagues who regularly treat patients with UC.

Active ulcerative colitis of any extent not responding to 5-ASA (fig. 1)

The first line treatment of mild to moderate left sided UC or pancolitis is combined topical and oral aminosalicylates [20]. The combination of oral and rectal mesalazine seems to be superior to either therapy alone in patients with extensive colitis [21]. 5-ASA is superior to placebo for induction of remission. In cases of failure to induce global or clinical improvement or remission, the pooled Peto odds ratio is 0.40 (95% confidence interval (CI), 0.30 to 0.53) [22]. Patients with a first flare or patients with a maximum of one flare per year requiring systemic steroids should be started on 0.75–1 mg/kg of oral prednisone-equivalent for two to four weeks [15, 20, 23–25]. After successful tapering of the steroids, maintenance therapy with topic and/or oral 5-ASA can be re-established [22, 26–28]. If remission cannot be maintained, the next course of oral steroids should be combined with azathioprine (AZA) or mercaptopurine (6-MP) at 2–2.5 mg/kg or 1–1.5 mg/kg, respectively [15, 20, 29, 30].

In a patient not responding to oral steroids, infection must be excluded. Stool cultures for bacteria and parasites and an assay for clostridium (Cl.) difficile must be obtained [31]. Sigmoidoscopy should be performed to confirm the diagnosis and to exclude cytomegalovirus (CMV) infection [32, 33]. If infection is excluded, treatment failure in this situation is called steroid-refractory. This topic will be discussed in the corresponding section below.

If a patient fails to taper corticosteroids within less than 16 weeks or a patient relapses within 12 weeks after corticosteroid discontinuation they are considered to be steroid-dependent (see the corresponding section below).

In a patient requiring more than one cycle of systemic steroids per year or in a patient with a poor projected prognosis (e.g., young age, severe first flare, severe systemic inflammation, slow response to steroids), oral prednisone-equivalent should be combined with azathioprine (AZA) or mercaptopurine (6-MP) at 2–2.5 mg/kg or 1–1.5 mg/kg, respectively [15, 20, 29, 30].

If tapering of the steroids is successful, maintenance-therapy with AZA/6-MP at the mentioned dose should be continued. In case of failure of this treatment including a trial with intravenous steroids (and excluding infection), the patient is considered as steroid-refractory. Further treatment will be discussed in the corresponding section. If a patient has had a full dose of AZA/6-MP for more than 12 weeks and fails to taper corticosteroids within 16 weeks, or relapses within 12 weeks after cessation of steroids, they are considered as steroid-dependent and an AZA/6-MP failure and should be treated according to the appropriate algorithm below.

---

**Table 1: Disease Activity in UC, adapted from Truelove and Witts (11)**

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Light clinical symptoms, but which can be worsened by the subjective perception of the patient.</td>
<td>Increased clinical symptoms but only mild systemic symptoms.</td>
<td>Severe active ulcerative colitis is best defined by Truelove and Witts’ Criteria.</td>
</tr>
<tr>
<td></td>
<td>Especially urgencies contribute to a more severe perception of the disease.</td>
<td>Steroid use is a good criterion to classify a patient as moderate (or severe).</td>
<td>Patients should be admitted to hospital for intensive treatment</td>
</tr>
<tr>
<td></td>
<td>Localization of the disease is important as topical treatments will have to be adjusted accordingly.</td>
<td>Presence of mucosal friability (bleeding on light contact with the rectal mucosa on sigmoidoscopy).</td>
<td></td>
</tr>
<tr>
<td>Bloody stools per day</td>
<td>≤ 4</td>
<td>≥ 4</td>
<td>≥ 6</td>
</tr>
<tr>
<td>Pulse</td>
<td>&lt; 90 bpm</td>
<td>≤ 90 bpm</td>
<td>&gt; 90 bpm</td>
</tr>
<tr>
<td>Temperature</td>
<td>&lt; 37.5 °C</td>
<td>≤ 37.5 °C</td>
<td>&gt; 37.8 °C</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>&gt; 11.5 g/dl</td>
<td>≥ 10.5 g/dl</td>
<td>&lt; 10.5 g/dl</td>
</tr>
<tr>
<td>ESR</td>
<td>&lt; 20 mm/h</td>
<td>≤ 30 mm/h</td>
<td>&gt; 30 mm/h</td>
</tr>
<tr>
<td>CRP</td>
<td>Normal</td>
<td>≤ 30 mg/L</td>
<td>&gt; 30 mg/L</td>
</tr>
</tbody>
</table>
Steroid-dependent ulcerative colitis (fig. 2)

Steroid-dependent ulcerative colitis defines a patient who fails to taper steroids below 10 mg within 16 weeks from a starting dose of 0.75–1 mg/kg oral prednisone-equivalent, or who relapses within 12 weeks after steroid discontinuation [31]. In this situation, compliance to 5-ASA must be checked first. Infection as a cause for therapy-failure must be ruled out by appropriate stool tests. CMV colitis should be excluded by sigmoidoscopy with biopsies. Before introducing azathioprine or mercaptopurine, a full blood count including absolute lymphocyte numbers must be obtained. Measurement of the activity of Thiopurin-S-Methyltransferase (TPMT) can be considered to identify patients at high risk for severe myelodepression under therapy with thiopurines [34–36]. Alternatively, regular testing of the full white blood count (WBC) is mandatory. Azathioprine is significantly more effective than mesalazine at inducing clinical and endoscopic remission in the treatment of steroid-dependent UC [30].

Any patient with steroid-dependent ulcerative colitis or with an early relapse is best started on azathioprine (AZA) at 2–2.5 mg/kg. In case of gastrointestinal intolerance or a flu-like syndrome, after exclusion of pancreatitis or hepatopathy, a switch to mercaptopurine (6-MP) at 1–1.5 mg/kg can be done. AZA/6-MP needs at least 12 weeks to be fully effective. AZA/6-MP failure is present, if a patient fails to taper corticosteroids after 12–24 weeks of full dose therapy or if the patient relapses within 12 weeks after steroid tapering. Again, compliance must be secured and infection ruled out. In this clinical scenario, induction treatment with infliximab at 5–10 mg/kg can be considered with infusions given at week 0, 2 and 6 followed by an infusion every 8 weeks [37]. As an alternative, oral tacrolimus at 0.1–0.2 mg/kg may be tried [16, 38]. The targeted trough level for induction therapy is 10–15 ng/ml [39]. A patient who is still refractory to treatment should be referred to a specialised centre with profound experience in IBD and adequate infrastructure. Surgery must always be considered as an alternative in the refractory patient.

Steroid-refractory ulcerative colitis (fig. 3)

A patient not responding to 0.75–1 mg/kg of oral prednisone-equivalent within two to four weeks is defined as steroid-refractory ulcerative colitis [10, 31]. This diagnosis is made after exclusion of an infection and is best re-assessed by colonoscopy and biopsy to confirm the diagnosis and/or to rule out complications.

If the patient is in a stable clinical condition without the need for rapid induction, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg should be added [20]. If there is still no remission after a full dose within 12–24 weeks, a switch to infliximab at 5–10 mg/kg at week 0, 2 and 6 followed by an infusion every 8 weeks [17, 37, 40] should be considered. If the patient is still refractory to this treatment, a third-line immunosuppressive therapy or surgery must be considered. This patient should or must be referred to a specialised centre.

If there is a need for rapid induction of remission in a severely ill patient and the patient is AZA-naïve, steroids must be given intravenously. Intravenous (iv) steroids (such as 60 mg of methylprednisolone or 400 mg of hydrocortisone daily) remain the mainstay of conventional therapy [20, 41]. Higher doses are not more effective, but lower doses are less effective [42, 43]. The expected overall response rate of steroids is 67% [43]. In case of response to treatment, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg should be added and steroids can be slowly tapered. If there is no response to iv-steroids after 2 weeks, intravenous cyclosporin at a dose of 2 mg/kg should be started [20, 44, 45]. Cholesterol levels should be checked before the start of cyclosporine. A prophylaxis against pneumocystis jiroveci may be installed [46, 47] as a combined immunosuppression entails an increased risk. In case of response to i.v. cyclosporine, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg...
should be added and oral cyclosporine should be continued for at least three month as a bridging therapy [16]. In case of non- response within two weeks, third-line immunosuppressive therapy or surgery must be considered at a specialised centre.

If a patient was a prior AZA/6-MP failure, infliximab at 5 mg/kg can be started [48–52]. In case of lack of response after two infusions or no remission after ten weeks, the dose should be doubled to 10 mg/kg. In a patient still not responding, third-line immunosuppressive therapy or surgery must be considered at a specialised centre.

Acute (fulminant) ulcerative colitis (fig. 4)

Acute severe or fulminant ulcerative colitis is best defined according to the index of Truelove and Witts (table 1) [11]. It defines a patient with a bloody stool frequency of more than five per day AND tachycardia >90 bpm, OR a temperature >37.8°, OR anaemia with a haemoglobin <10.5 g/dl, OR an elevated CRP (>30 mg/l) or ESR (>30 mm/h), respectively. A patient fitting these criteria must be admitted to hospital and needs intensive treatment.

First line treatment is intravenous application of steroids such as 60 mg of methylprednisolone or 400 mg of hydrocortisone daily [20, 41]. If the AZA-naïve patient does not respond (sustained fever, bloody diarrhoea more than 4 times daily or continued elevated CRP) on day 3–7, iv ciclosporin or infliximab should be started [20]. Cyclosporin is given at a dose of 2 mg/kg [20, 44, 45] after exclusion of hypomagnesaemia. Ciclosporin trough levels must be checked on day 3, dependent on the assay and the local laboratory (it should be between 300 and 500 ng/ml). In case of clinical improvement, AZA at 2–2.5 mg/kg or 6-MP at 1–1.5 mg/kg should be started before discharge and oral ciclosporin should be continued for at least three months as a bridging therapy [16]. If no improvement is achieved within 5–7 days, infliximab may be tried or colectomy must be performed.

As an alternative to ciclosporine, infliximab may be started with 5 mg/kg at week 0, 2 and 6 [48–52, 54]. If no clinical improvement occurs within 7–10 days or a deterioration is developing, surgery must be considered. In case of clinical improvement, infliximab should be continued at 5 mg/kg every 8 weeks.

Patients who are already on a therapy with AZA/6-MP at the time of their severe flare seem to respond poorly to ciclosporin [55, 56]. If they fail iv-steroids, infliximab should be started at 5 mg/kg and continued every 8 weeks if an improvement occurs. In case of failure or deterioration, surgery must be considered. Tacrolimus may be an alternative in specialised centres [20, 39, 57, 58].

Conclusions

The care for a patient with moderate to severe ulcerative colitis remains challenging despite the fact that morbidity and mortality rates have been considerably reduced during the last 30 years. 5-ASA, thiopurines and infliximab are well established treatment regimens for the maintenance of remission. 5-ASA are considered the standard in treating mild to moderate UC. For inducing remission in refractory patients and in severe disease cases, corticosteroids remain the first line therapy. With the administration of ciclosporin and infliximab as rescue therapies in severe refractory cases, morbidity and mortality can be clearly reduced. The early detection and/or the prophylaxis of complications, better intensive care and the improvement of anaesthesiological and surgical techniques have contributed to better outcomes. One of the most important factors remains the close teamwork between the gastroenterologist and the surgeon at all times during the clinical course in order not to miss the best timing for colectomy, which will still be necessary in about 30% of the patients with severe ulcerative colitis.

Funding / potential competing interests: The work was supported by an unrestricted grant from MSD. Data interpretation and writing of this report were done in collaboration with the co-authors independently of MSD. Christoph Beglinger is advisory board member at MSD and Abbott and has recieved grant support from MSD, Abbott and Roche. Michael Manz was supported by a grant from Essex. Pierre Michetti served as consultant for MSD, Abbott, UCB, Merck-Serono, Bertex, AstraZeneca. Gerhard Rogler has consulted to Abbott Switzerland, MSD Switzerland, Novartis, Roche, UCB Switzerland, Falk and Tillots; has recieved speaker honoraria from Abbott, Astra Zeneca, Essex/MSD, Falk, Tillots, UCB, Vifor; has recieved grant support from Abbott, Essex/ MSD, Falk, Novartis, Roche, Tillots, UCB, Zeller.

Correspondence: Dr. Michael Manz, Department of Gastroenterology, St. Claraspital Basel, Postfach, CH-4016 Basel, Switzerland, Michael.Manz@claraspital.ch

References

26 Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane database of systematic reviews (Online). 2006;CD000544.


STERIOD-DEPENDENT ULCERATIVE COLITIS

0.75–1 mg/kg oral Prednisone-equivalent

- Fail to taper within ≤ 16 weeks or
- Relapse within 12 weeks after Steroid discontinuation

- Check compliance to 5-ASA
- Monitor blood

- Exclude infection
- Measure TPMT

AZA 2–2.5 mg/kg

- Full AZA/6-MP dose during ≥ 12 weeks and Fail to taper CS within ≤ 16 weeks or Relapse within 12 weeks after CS discontinuation

- No signs of pancreatitis
- Check compliance and dose
- Liver transaminases

- Gastrointestinal intolerance or flu-like syndrome

AZA failure

Infliximab 5–10 mg/kg (or oral Tacrolimus)

Refractory to treatment*

Consider surgery

6-MP 1–1.5 mg/kg

Treatment failure

*3rd line immunosuppressive therapy restricted to specialized centers
STEROID-REFRACTORY UCERATIVE COLITIS

0.75–1 mg/kg oral Prednisone-equivalent within 2–4 weeks

– Exclude infection

Need for rapid induction of remission

AZA- naïve

No need for rapid induction

Prior AZA failure

No response within ≤ 2 weeks

No response after 2 infusions or no remission after 8–10 weeks

iv Steroids

Response within ≤ 2 weeks

No remission at full dose within 10–12 week or loss of remission

Infliximab 5 mg/kg

Infliximab 10 mg/kg

Infliximab 5–10 mg/kg (±/- AZA)

AZA 2–2.5 mg/kg / 6-MP 1–1.5 mg/kg (Oral Ciclosporin for 3 months)

Infliximab failure

Infliximab failure

Refactory to treatment*

Consider surgery

* 3rd line immunosuppressive therapy restricted to specialized centers

---

ACUTE (FULMINANT) UCERATIVE COLITIS

Patient with acute symptoms defined by Trueove and Witts

iv Steroids

AZA naïve patient

Prior AZA failure

Day 3–7 assessment:
– Sustained fever?
– Bloody diarrhoea (>4x daily)?
– Elevated CRP?

iv Ciclosporin 2–4 mg/kg

Infliximab 5 mg/kg, 3 infusions w0, w2, w6

Infliximab 5 mg/kg, 3 infusions w0, w2, w6

Clinical Improvement

CUC trough level on day 3

No improvement within 5–7 days

No clinical improvement within 7–10 d or deterioration

Surgery or Infliximab**

5 mg/kg

Surgery or 3rd line Immuno-suppression**

Continue Infliximab 5 mg/kg every 8 weeks

Surgery or 3rd line Immuno-suppression**

Oral Ciclosporin for 3 months

Start AZA 2–2.5 mg/kg before discharge

Check CUC trough level

Clinical improvement

No clinical improvement within 7–10 d or deterioration

---

* 3rd line immunosuppressive therapy restricted to specialized centers

** 3rd line immunosuppressive therapy restricted to specialized centers